130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
Rank Status Study
21 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Env 2-3
22 Completed Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: MRKAd5 HIV-1 gag/pol/nef
23 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults
Condition: HIV Infections
Interventions: Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1;   Biological: QS-21;   Biological: rgp120/HIV-1MN
24 Completed A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (MicroGeneSys)
25 Completed A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
26 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA009-00-VP;   Biological: VRC-HIVADV014-00-VP
27 Active, not recruiting Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad26.ENVA.01 (rAd26);   Biological: Placebo Vaccine
28 Completed A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
29 Completed A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
30 Completed Safety of the EnvPro HIV Vaccine in Healthy Volunteers
Condition: HIV Infections
Intervention: Biological: EnvPro
31 Completed Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-1 gag DNA;   Biological: HIV-1 gag DNA plus IL-12 DNA adjuvant;   Biological: CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine);   Biological: Sodium chloride injection (0.9%)
32 Completed A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects
Condition: HIV Infections
Intervention: Biological: HIV-1 Peptide Immunogen, Multivalent
33 Unknown  Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers
Conditions: HIV-1;   HIV Infections
Intervention: Biological: MVA.HIVA
34 Completed Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVADV014-00-VP;   Biological: VRC-HIVDNA016-00-VP
35 Not yet recruiting Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B
Condition: HIV Infections
Intervention: Biological: Experimental
36 Completed Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa
Condition: HIV Infections
Interventions: Biological: AVX101;   Other: placebo
37 Completed Analysis of Immune Responses to HIV Vaccines
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention:
38 Active, not recruiting Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
39 Completed Early Immune Responses to Vaccination - A Substudy to HVTN 205
Condition: HIV Infections
Interventions: Biological: JS7 DNA vaccine;   Biological: MVA/HIV62 vaccine
40 Completed Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years